Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: Baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study
- PATTI F
- AMATO MP
- TROJANO M
- BASTIANELLO S
- TOLA MR
- GORETTI B
- CANIATTI L
- DI MONTE E
- FERRAZZA P
- BRESCIA MORRA V
- LO FERMO S
- PICCONI O
- LUCCICHENTI G
- VECCHIO R
- MAIMONE D
- MESSINA S
- GASPERINI C
- OREFICE V
- FLORIO C
- PORTACCIO E
- ZIPOLI V
- BERTOLOTTO A
- BRAMANT P
- SESSA E
- CENTONZE D
- COTTONE S
- SALEMI G
- FALCINI M
- GALLO P
- PERINI P
- GIGLI, G.L
- GIULIANI G
- GRIMALD LM
- MURRI L
- LUGARESI A
- MONACO F
- MONTANARI E
- MOTTI L
- NERI S
- PACIELLO M
- PROVINCIALI L
- RAGNO M
- ROSATI G
- RUGGIERI S
- TOLA MR
- TONALI P
- BATOCCHI AP
- DE CARO MF
- GHEZZI A
- ZAFFARONI M
- ZOLO P
- ZORZON M
- SIGNORINO M
- SCARPINI E
- DURELLI L
- CAROLEI A
- TODARO M
- SPITALERI D
- TARTAGLIONE A
DOIAbstract
The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNbeta-1a) on cognition in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Patients aged 18-50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score <or=4.0) were assigned IFNbeta therapy at the physician's discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNbeta-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for cognitive impairment over three years (44...
Add to ORKG